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ABSTRACT 
Objective:  This  investigation  was  undertaken  to  determine  the  reference  values  of  specific 
biochemical markers that have been have been associated with behavior typical of ADHD in a 
group of patients before and after metabolic correction. 
 
Background:  Attention  deficit  hyperactivity  disorder  (ADHD)  affects  approximately  two 
million  American  children,  and  this  condition  has  grown  to  become  the  most  commonly 
diagnosed  behavioral  disorder  of  childhood.    According  to  the  National  Institute  of  Mental 
Health (NIMH), the cause of the condition, once called hyperkinesis, is not known.  
The  cause  of  ADHD  is  generally  acknowledged  to  be  multifactorial,  involving  both 
biological  and  environmental  influence.    Molecular,  genetic,  and  pharmacological  studies 
suggest  the  involvement  of  the  neurotransmitter  systems  in  the  pathogenesis  of  ADHD. 
Polymorphic variants in several genes involved in regulation of dopamine have been identified, 
and related neurotransmitter pathways alterations are reported to be associated with the disease. 
Nutritional deficiencies, including deficiencies in fatty acids (EPA, DHA), the amino acid 
methionine, and the trace minerals zinc and selenium, have been shown to influence neuronal 
function and produce defects in neuronal plasticity, as well as impact behavior in children with 
attention deficit hyperactivity disorder.  
 
Materials/Methods: This study was based on data extracted from our patient history database 
covering a period of over ten years. We performed laboratory tests in 116 patients 2.7-25 years 
old with a diagnosis of ADHD. Sixty-six percent (66%) of patients were males.  Patients were Functional Foods in Health and Disease 2013; 3(1):1-20     Page 2 of 20                                                 
followed from 3 month to 3 years. We compared the distributions of fatty acids, essential metals, 
and the levels  of metabolic stress  factors with  established reference ranges before and  after 
interventions.  In addition, we analyzed the association between toxic metal concentrations and 
the levels of essential metals. 
 
Results: This study was based on data extracted from our patient history database covering a 
period of over ten years. We performed laboratory tests in 116 patients 2.7-25 years old with a 
diagnosis of ADHD. Sixty-six percent (66%) of patients were males.  Patients were followed 
from 3 month to 3 years. We compared the distributions of fatty acids, essential metals, and the 
levels of metabolic stress factors with established reference ranges before and after interventions.  
In addition, we analyzed the association between toxic metal concentrations and the levels of 
essential metals. According to these data, the metabolic correction of ADHD by supplementation 
with minerals, vitamins, essential fatty acids, and amino acids can ameliorate ADHD symptoms. 
Eighty  percent  (80%)  of  children  who  were  treated  from  several  weeks  to  1-2  years, 
demonstrated improvement of metabolic stress level, measured by pyrroles. For these patients 
the levels of EPA were increased and the omega-6/omega-3 ratio was improved.   
 
Conclusion:  In  the  studied  population  it  was  demonstrated  that  metabolic  correction  of 
biochemical disturbances using essential fatty acids, amino acids, and minerals can improve fatty 
acid profiles and metabolic stress levels. These disturbances or variations from reference values 
have been associated with behavior typical of ADHD. Further studies need to be conducted with 
integrative metabolic correction therapy to determine its value in the management of ADHD. 
 
Key  words:    Attention  deficit  hyperactivity  disorder,  metabolic  correction,  fatty  acid 
composition, essential metals, toxic metals, pyrroles, vitamins and minerals. 
 
 
BACKGROUND: 
According to the National  Institute of Mental  Health, attention deficit hyperactivity disorder 
(ADHD) affects approximately two million American children; 3 to 5 percent of the school-age 
population, and is about four times more common in boys than in girls [1-4].  Over the past 
several decades this condition has grown to become the most commonly diagnosed behavioral 
disorder of childhood.  According to NIMH, the cause of the condition, once called hyperkinesis, 
is not known.  
ADHD is primarily characterized by a persistent pattern of inattention and/or hyperactivity-
impulsivity  that  is  more  frequent  and  severe  than  is  typically  observed  in  individuals  at  a 
comparable level of development [5, 6]. The cause of ADHD is generally acknowledged to be 
multifactorial, involving both biological and environmental influences [7].  Molecular, genetic, 
and pharmacological  studies  suggest  the involvement of the dopaminergic, serotonergic,  and 
noradrenergic neurotransmitter systems in the pathogenesis of ADHD. Polymorphic variants in 
several  genes  involved  in  regulation  of  the  dopamine  have  been  identified  and  related 
neurotransmitter pathways alterations are reported to be associated with the disease [8-9]. Functional Foods in Health and Disease 2013; 3(1):1-20     Page 3 of 20                                                 
Nutritional deficiencies, including deficiencies in the long chain polyunsaturated fatty acids 
(PUFA) eicosapentaenoic acid (EPA; 20:5n–3) and docosahexaenoic acid (DHA; 20:6n-3), the 
amino acid methionine, and the trace minerals zinc and selenium, have been shown to influence 
neuronal  function  and  produce  defects  in  neuronal  plasticity,  as  well  as  impact  behavior  in 
children with attention deficit hyperactivity disorder. Neurons lacking in plasticity are a factor in 
neurodevelopmental  disorders  such  as  ADHD,  autism,  and  mental  retardation.    Essential 
nutrients help maintain normal neuronal plasticity.  Among dietary factors, learning and behavior 
are influenced not only by nutrients, but also by exposure to toxic food contaminants such as 
lead, mercury, arsenic, and aluminum that can disrupt metabolic processes and alter neuronal 
plasticity. Toxic heavy metals are found in the air we breathe, the food we eat, and the houses we 
live in.  Toxic metal exposure can result in a wide array of common mental health disorders.  The 
results  of  studies  demonstrate  that  there  are  neurochemical  and  behavioral  consequences  of 
heavy metal exposure during brain development.  
In addition, nutritional deficiencies and toxic metal exposure have been shown not only to 
alter  neuronal  function,  but  to  increase  metabolic  stress  among  children  with  autism.  These 
factors may be directly related to the development of behavior disorders and learning disabilities. 
The role of n–3 PUFA’s in child mental health has received recent attention related to the 
treatment  of  attention-deficit  hyperactivity  disorder.  The  association  between  EFA  and 
hyperactivity was initially hypothesized in the 80’s [10]. This hypothesis is compatible with 
lower  blood  EFA  fractions  in  children  with  ADHD  compared  with  matched  comparisons.  
Several recent studies have examined the relation between n–3 PUFAs and children’s behavioral 
problems, depressed mood, and clinical depression [13-16]. The fatty acids that are biologically 
relevant for mental health include the long-chain n–3 FAs that are present in cell membranes in 
the brain and neural tissue, namely docosahexaenoic acid and eicosapentaenoic acid.  Although 
the exact mechanisms by which PUFAs, especially DHA and EPA, affect behavioral disorders 
such as ADHD remain unclear, plausible evidence suggests why DHA and EPA may be involved 
in these disorders. DHA and EPA are important for both membrane fluidity and neurotransmitter 
function, especially synaptic signal transduction, particularly during the perinatal period [11, 12]. 
Summary of studies on blood essential fatty acid (EFA) status in children with attention-deficit–
hyperactivity disorder is presented in a review [13]. Cross-sectional studies have reported that 
the frequency of behavioral problems is inversely associated with n–3 PUFA status [14, 15]. 
Several  case  control  studies  [16-18]  have  reported  low  blood  concentrations  of  DHA  and 
arachidonic acid (AA) in children with ADHD compared with age-sex matched control subjects. 
Finally, several recent longitudinal studies found a negative association between DHA status 
early in life and subsequent behavior problems in young children [19-21]. These data suggest 
children and adolescents with ADHD continue to display abnormal essential fatty acid profiles 
that are different from normal controls of similar age, and there are metabolic differences in fatty 
acid handling between ADHD children and normal controls.  
One of the hypotheses that link EFA to ADHD is that children with ADHD might suffer 
from slower conversion of linoleic acid and alpha linolenic acid to long chain PUFA. A recent 
genetic study supports this direction [22].  
Other studies mounted evidence suggesting a central role for transition bio-metals in the 
etiopathogenesis of ADHD. Indeed, while studying the molecular basis for this heterogeneous Functional Foods in Health and Disease 2013; 3(1):1-20     Page 4 of 20                                                 
group  of  diseases,  it  has  become  increasingly  evident  that  bio-metals  and  non-physiological 
metals [23-30] are often involved in pathology onset and progression, either by affecting the 
conformation of specific proteins or by exacerbating local metabolic stress.  For example, the 
deficiency  of  zinc,  which  is  involved  in  the  production  and  modulation  of  melatonin,  is 
considered to be a factor in ADHD [31-33]. Zinc is an essential co-factor of more than 100 
enzymes, including metalloenzymes, which are necessary in the metabolism of carbohydrates, 
fatty  acids,  proteins,  and  nucleic  acids.  It  is  an  important  factor  in  the  metabolism  of 
neurotransmitters, prostaglandins, and for maintaining brain structure and function. 
In  a  study  [34],  it  was  shown  that  red  cell  magnesium  (Mg)  concentrations  of  ADHD 
children were below a critical value of 2.2mmol/L. In addition Mg depletion has long been 
known to cause hyperexcitability with convulsive seizures in rodents [35].  Metabolic disorders 
and genetic alterations are suspected in this pathology, in which Mg transport and intracellular 
distribution may be reduced and can be reversed by treatment [36, 37].  In addition, Mg is 
involved in control of some CNS processes.  
Many treatment methods of ADHD have been tried, with the most common approach being 
psychiatric intervention and use of prescription drugs such as methylphenidate (Ritalin) with 
mixed results and an array of multiple side-effects.  
The  purpose  of  this  study  is  to  evaluate  if  the  metabolic  correction  of  pathologic 
biochemical–physiological  disturbances  associated  with  ADHD  can  be  resolved  by 
administering target nutrients.  
 
METHODS: 
ADHD  diagnosis  was  made  by  qualified  medical  doctors,  based  on  direct  observation  plus 
reports by multiple sources (parents and other caretakers).  
Laboratory tests were done and analyzed for 116 patients 2.7-25 years old (mean age 12 
years old). Thirty-four % of patients were females and 66% males.  Patients were followed from 
3 months to two-three years.  
The  protocol  for  patients  with  ADHD  included  evaluations  of  fatty  acid  composition, 
essential metals, toxic metals (in blood and hair), food allergies, levels of urinary  pyrroles, and 
the levels of vitamins before, during, and post treatment.    
For all patients, we compared the distributions of fatty acids, essential metals, and the levels 
of metabolic stress factors with established reference ranges for these parameters.  In addition, 
we  analyzed  the  association  between  toxic  metal  concentrations  and  the  levels  of  essential 
metals.  
 
Treatment and follow-up 
Children and adolescents were administered an integrative protocol for ADHD treatment, similar 
to a protocol developed by Gant [38-40]. This treatment of ADHD is based on the metabolic 
correction  of  biochemical  abnormalities  associated  with  ADHD.  This  safe,  evidence  based 
approach  gives  the  patient  an  opportunity  to  respond  prior  to  considering  more  toxic 
pharmaceutical approaches.  The treatment includes supplementation with minerals, vitamins, 
omega-3 and omega-6 essential fatty acids, flavonoids, probiotics, dietary modifications, and 
chelation of toxic metals by natural substances.  Functional Foods in Health and Disease 2013; 3(1):1-20     Page 5 of 20                                                 
 
Statistical methods/data collection 
This study was not a controlled experiment, but rather a mining of data from our patient history 
database covering a period of over ten years. 
For statistical analysis Systat software (Systat, Inc) and Kaleidagraph software were used. 
Variables  were  presented  as  mean  values  ±  SD,  or  as  medians  with  corresponding  25th 
percentiles.    Association  between  different  factors  was  assessed  using  linear  models  and 
polynomial model.  Statistical significance was accepted if the null hypothesis could be rejected 
at p≤0.05. 
 
RESULTS: 
The analysis of the imbalances and deficiencies found for this group of patients is presented 
below.  
 
Laboratory tests of patients with ADHD    
Essential fatty acids  
The fatty acids of interest for our analysis were the n-6 and n-3 PUFA. In particular, the fatty 
acids linoleic acid (18:3n-6, LA) and alpha-linolenic acid (18:3n-3, ALA) are called essential 
fatty acids (EFA) as they cannot be synthesized by the human body and, therefore, have to be 
provided by the diet. The other n-3 and n-6 fatty acids can be synthesized by humans from LA 
and ALA, respectively.  
As it was previously mentioned, the imbalance of fatty acids, reduction in essential metals, 
increased  level  of  toxic  metals,  and  augmented  level  of  stress  are  the  characteristics  and, 
probably, underlined primary causes of the ADHD condition. Many studies have shown that 
omega-3 fatty acid deprivation during development results in altered performance in learning 
tasks, altered activity of membrane receptors and proteins, and altered metabolism of several 
neurotransmitters  including  dopamine.  Relevant  studies  suggest  that  omega-3  fatty  acids 
deficiency decreases the mean cell body size of neurons in the hypocampus, hypothalamus, and 
cortex [13]. Lower levels of omega-3 fatty acids correlate with a higher score on the behavioral 
scale for patients with ADHD [18]. 
Data presented in Table 1 are baseline and show the mean and SD of the percentage of fatty 
acids, reference range (RR), and percentage of patients with higher and lower level of EFA than 
reference range.  
Analyzed distribution of docosahexaenoic acid (22:6n-3, DHA) for patients with ADHD 
demonstrated that the 16% of the patients had the levels of this fatty acid lower than reference 
range (mean-2SD) and for 40% of patients the level of DHA was less than average value of RR. 
The DHA has an important structural role: it comprises 10% to 20% of human brain total 
fatty acid composition, and it is the most predominant n-3 fatty acid found in the brain.  DHA is 
important for both membrane fluidity and neurotransmitter function, especially synaptic signal 
transduction. 
Summary of the relative plasma fatty acid composition in patients with ADHD is presented 
in Table 1.  
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 Table 1.  Relative plasma fatty acid composition in patients with ADHD 
 
Relative plasma fatty acid composition in patients with ADHD    
Fatty acid  Mean (%) 
Standard 
Deviation  
Double 
bond 
Reference  range 
(% of total) 
Higher 
than RR 
Lower 
than RR 
n-3 series          
   
 
alpha linolenic  0.15  0.05  18:3n-3  0.1-0.2     17% 
Eicosapentaenoic (EPA)  0.38  0.21  20:5n-3  0.3-0.6     55% 
Docosahexaenoic (DHA)  3.00  0.25  22:6n-3  2.0-5.9     16% 
total omega 3  3.90  1.95     3.0-5.0      42% 
omega 6 series                   
Arachidonic  14.09  1.98  20:4n-6  12.0-17.0       
Dihomogammalinolenic   1.62  0.46  20:3n-6  1.0-2.0       
Gamma-linolenic  0.05  0.04  18:3n-6  0.04-0.07     50% 
Linoleic  11.34  1.70  18:2n-6  9-14       
 ratios                   
AA/EPA  20.77  13.04     5.0-20  48%    
omega6/omega3  8.14  3.63     1.5-8  60%    
 
Deficits in the frontal cortex dopamine neurotransmission seen in patients with ADHD could 
be associated with lower brain DHA concentration. Low DHA status is associated with poor 
development of visual acuity and low indices of neural development in human infants. 
The eicosapentaenoic acid (20:5n-3, EPA) is also an n-3 long-chain fatty acid that is less 
abundant in neural (membrane) structures, but has numerous roles in neural, enzymatic, and anti-
inflammatory functions.  The distribution of this fatty acid in ADHD patients is presented in 
Figure  1  (bar  shows  the  reference  range  estimated  from  the  same  age  population  without 
ADHD).  According to these data 50% of patients had a level of EPA lower than reference range.   
In addition, the ratio of arachidonic acid to EPA demonstrated the abnormal distribution in 
patients  with  ADHD.    In  the  n-6  family,  arachidonic  acid  (20:4n-6,  AA)  is  an  important 
structural lipid in the neural membranes. According to the previous studies, the arachidonic acid 
to  eicosapentaenoic  acid  ratio  in  blood  correlates  positively  with  clinical  symptoms  of 
depression, bipolar affective disorder, and reactive depression.  
Our analysis of patients with ADHD demonstrated that there was increased level of this ratio 
that supports the presence of stress in patients with ADHD conditions. Reference range of the 
ratio AA/EPA is between 5 and 13.  Distribution of this ratio for patients showed that 70% of 
children and adolescents had ratio levels higher than the normal range. This result provides a 
basis for the nutritional supplementation of subjects with ADHD, aimed at reducing the AA/EPA 
ratio.  Functional Foods in Health and Disease 2013; 3(1):1-20     Page 7 of 20                                                 
Figure 1. Distribution of eicosapentaenoic fatty acid in plasma of patients with ADHD before 
treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The analysis of the data of fatty acids in omega 6 series showed that children with ADHD have 
lower levels of EFAs in omega-6s in addition to omega-3s. 
Regarding the omega 6 fatty acids, gamma-linolenic acid (GLA) was significantly lower in 
patients with ADHD (Figure 2).  
  
Figure  2.  Distribution  of  gamma-linolenic  acid  in  plasma  of  patients  with  ADHD  before 
intervention. 
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As GLA is an n−6 fatty acid that has anti-inflammatory properties, the decreased level of 
this fatty acid can lead to increased level of inflammation in patients with ADHD. 
Excessive amounts of omega-6 polyunsaturated fatty acids and a very high omega-6/omega-
3 ratio was also measured for patients with ADHD. 
Our analysis demonstrated that for patients with ADHD there were higher levels of omega 6 
and lower level of omega 3 fatty acids (Figure 3).  Maximum of the ratio distribution was in the 
range of 9-10 and 50% of patients had omega6/omega3 levels higher than 8.   
 
Figure  3.    Omega-6  to  omega-3  ratio  measured  in  plasma  of  patients  with  ADHD  before 
treatment.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Urinary pyrroles in patients with ADHD 
Pyrroles or "Mauve Factor," a metabolic product of hemoglobin, was first detected in the urine of 
psychiatric  patients  by  the  Hoffer  group  in  1958  and  named  for  its  appearance  on  paper 
chromatograms. Irvine extracted the compound from urine, correctly assigned the structure to the 
pyrrole family, and conferred the common name [40-42].  Hoffer observed that recovery from 
acute schizophrenia, associated with disappearance of Mauve from the urine, regression with 
reappearance [43-48]. Large doses of vitamin B6 suppressed Mauve in schizophrenics. Later it 
became clear that Mauve is not confined to schizophrenia. Mauve elevation is documented in 
many cognitive, affective, and neurobehavioral disorders. According to the studies [45] elevated 
levels of pyrroles can be found in patients with schizophrenia (59%-80%), depression (12%-
46%), autism (46%-48%) and ADHD (40%-47%). Combined treatment by vitamin B6 and zinc 
suppressed Mauve and improved symptoms in many neurobehavioral disorders. 
Despite that the high level of pyrroles was described in the urine of patients with various 
mental illnesses, how pyrroles are produced and appear in the urine is still unclear. Pyrrole is 
from subclass of monopyrroles, well known for biotoxicity, and an elevated level of excretion 
classically associated with emotional stress. The suggestion is that the pyrroles in urine may be 
the result of an aberration of porphyrin metabolism (in conditions of iron deficiency, unstable 
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hemoglobin  disease,  RBC  hemolysis,  or  others).    The  test  of  pyrroles  or  HPL 
(hydroxyhemopyrrolin-2-one)  assay  is  based  on  the  extraction  of  pyrroles  from  urine  with 
chloroform  followed  by  reaction  with  Ehrlich’s  acid  aldehyde  reagent  (0.5  g  of  p-
dimethylaminobenzaldehyde, 2.5 ml sulfuric acid in 50 ml of methanol).  This preparation yields 
a chromophore with an absorption maximum of 540 nm.  For this test, urine samples of patients 
with ADHD were collected and 200-500 mg of ascorbic acid was added as a preservative (2.0 ml 
of urine for analysis).    
The level of pyrroles was measured in 116 patients. Sixty-five % of the patients had a level 
of pyrroles higher than upper normal limit (20ug/dL). The highest level was measured for a 10-
year  old  boy  (481ug/dL).  A  level  of  192ug/dL  was  found  in  5  year  old  girl  and  levels  of 
123ug/dL and 114ug/dL in two boys.    
We analyzed a correlation between the levels of pyrroles and histamine.  Histamine is an 
important  brain  neurotransmitter  and  neuro-regulator  that  is  present  in  all  nerve  cells. 
Degradation of histamine is through methylation; low histamine levels indicate over-methylation 
and high histamine level means that the process of re-methylation is overactive.  Histamine 
either directly or indirectly influences all other major neurotransmitters, often via inhibition of 
neurotransmitter release thus theoretically causing anxiety, depression, or both. The anxiety may 
be caused by histamine’s inhibition of GABA, which slows nerve transmission. Histamine can 
also release norepinephrine, thus potentially causing anxiety.  
Histamine  imbalance  exists  in  patients  with  mental  disorders.    Patients  with  a  mental 
disorder may have higher than normal and lower than normal levels of histamine. Histapenia 
describes the low histamine conditions and histadelia is term for elevated histamine.  
The level of histamine was screened for patients with ADHD.  Maximum of the distribution 
of histamine was on the upper level of the reference range (RR), which is 60 ng/ml, and half of 
the subjects had a level of histamine higher than the upper level of the RR. 
Distribution of the values of pyrroles for patients with ADHD is presented in Figure 4.  
 
Figure  4.  Distribution  of  the  levels  of  pyrroles  in  urine  of  patients  with  ADHD  before 
intervention  
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       We  found  histamine  imbalances  in  these  patients,  and  two  different  tendencies  in  the 
relations between the levels of histamines and pyrroles.  For patients with a mild increase in the 
level of pyrroles (values less than 45ug/dL), there was inverse association between pyrroles and 
histamine (Figure 5a).  For several patients with very high levels of pyrroles (higher than 45 
ug/dL), there was direct correlation between histamine and pyrrole levels (Figure 5b).    
 
Figure 5 (a, b).  Correlations between the levels of pyrroles and histamine 
 
ADHD and the levels of essential and toxic metals   
The measurements of the levels of the essential metals in plasma, red blood cells, and hair were 
made by clinical laboratory by inductively-coupled plasma-mass spectrometry.  Summary of the 
data is presented in Table 2.   
 
Table 2.  Essential metals in plasma in patients with ADHD 
Essential metals in plasma in patients with ADHD 
Essential metals 
Number of 
cases out of 
reference 
range 
Percentage 
of patients 
lower than 
RR 
Mean 
value 
Units  SD 
Reference 
range 
Percentage of 
patients higher 
than RR 
 
magnesium 
(hair)  35/68  53%  34.1  ug/g  38.5  25-90    
magnesium 
(RBC)  26/71  35%  5  mg/dL  0.67  4.5-6.4    
copper (hair)  36/124    33.2  ug/g  37.5  6-25 
37%  
(16 patients) 
>80ug/g 
zinc(hair)  11/68  16%  133.5  ug/g  36.8  100-180    
Zinc (RBC)  17/60  28%  10.3  ug/g  1.9  9-15    
selenium  (hair)  41/104  39%  2.0  ug/g  1.4  0.2-1.4    
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Several  minerals  were low in  ADHD patients.  The most pronounced deficiencies  were 
found for magnesium, selenium, and zinc. Data analysis demonstrated that many children with 
ADHD have lower zinc in relation to reference range (28% of patients had levels of zinc in red 
blood cells lower than RR).  
Our  data  showed  a  deficiency  of  magnesium  in  patients  with  ADHD.    Magnesium  is 
involved in control of some CNS processes. The prior clinical study has been reported on the 
effect of Mg supplementation on hyperactivity in children.   
Mg deficiencies were indicated by a subnormal concentration of Mg, determined by hair 
analysis (Figure 6) and red blood cell analysis. Fifty % of patients according to hair analysis and 
35% of patients according to RBC analysis had a level of Mg lower than reference range.      
Analysis of the distribution of selenium for these patients also demonstrated that 39% of 
patients had the levels of selenium lower than the reference range. Selenium is an important 
mineral for maintaining proper antioxidant balances, either directly (as an antioxidant itself) or 
indirectly (via its incorporation into selenium-dependent enzymes). The latter is evidenced by a 
number  of  important  enzymes  such  as  the  dependence  of  the  important  antioxidant  enzyme 
glutathione peroxidase on selenium.   
 
Figure 6.  Distribution of the magnesium levels in hair of patients with ADHD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In addition, copper, and zinc participate in SOD enzymatic mechanisms that protect against free 
radicals, and therefore, serve an important adjunct role in oxidative balance [50]. A diminished 
level of selenium can indicate an increased level of oxidative stress in these patients.   
0
2
4
6
8
10
12
14
0 10 20 30 40 50 60 70 80
Distribution of magnesium in patients with ADHD
 
n
u
m
b
e
r
 
o
f
 
c
a
s
e
s
Magnesium (hair analysis, ug/g)Functional Foods in Health and Disease 2013; 3(1):1-20     Page 12 of 20                                                 
In addition to the several essential metals mentioned above, a copper imbalance was found 
in ADHD children and adolescents.  Thirty-seven % of patients had a level of copper higher than 
the  upper  reference  level  25ug/g.  Copper  interferes  with  zinc  metabolism,  affects  thyroid 
activity, and enhances the biogenic amines (the neurotransmitters that stimulate brain activity). 
Copper appears to have many important functional roles in the body that apparently relate to, 
among others, the maintenance of the immune function, bone health, and homeostasis [51].  The 
element  is  needed  in  trace  amounts,  but  excess  is  toxic.  It  increases  lipid  peroxidation  and 
depletes glutathione reserves, which makes the organism more vulnerable to oxidative stress. 
Copper and zinc levels are regulated by metallothionein, a short linear protein composed of 61 
amino acid units. When this protein fails to perform its necessary functions, abnormal levels of 
nutrient  metals  (such  as  copper,  zinc,  and  manganese)  and  toxic  metals  (such  as  cadmium, 
mercury, and lead) can result.   
 Copper and zinc are in high concentrations in the brain hippocampus. As a result elevated 
copper and depressed zinc have been associated with hyperactivity, attention deficit disorders, 
behavior disorders, and depression. It has been suggested that high copper induces damage of 
dopaminergic neurons through destroying antioxidant defenses, such as it was demonstrated in 
animal studies by lowering Cu/Zn SOD levels in rats [57, 58]. 
Our results showed the deficiency of zinc in RBCs of 28% of patients and in hair of 16% of 
patients.  Several other studies have investigated the role of zinc in the etiology of ADHD and 
have suggested that zinc deficiency is associated with the pathophysiology of the disease [52- 
54].  Research  has  also  demonstrated  that  zinc  treatment  may  be  efficacious  for  ADHD 
individuals [55].  
We  analyzed  correlation  between  depressed  level  of  Zn/Cu  ratio  and  increased  level  of 
copper in patients with ADHD. The ratio of copper to zinc was chosen as this ratio is clinically 
more important than the concentration of either of these trace metals.  The relationship between 
Zn/Cu and Cu levels in ADHD individuals showed that the ratios were significantly lower when 
accompanied by high Cu levels (all values are measured by hair analysis).  
 
Effect of toxic metals on the levels of essential metals 
Our analysis demonstrated that toxic metals can substitute and deplete essential metals. The 
concentration of toxic metals measured in patients with ADHD is shown in Table 3. 
Examples of the relations between zinc, selenium and the concentration of toxic metals in 
hair are presented in Figure 7 (a, b) and show that the increased level of toxic metals results in 
the depletion of essential metals. 
 As toxic metals have a synergistic effect and lead and mercury have higher toxic effects on 
cells  in  the  body  than  do  other  heavy  metals,  the  total  concentration  of  heavy  metals  was 
estimated by summation of all concentrations with multiplication of the concentrations of Pb and 
Hg by a factor of ten. According to the data presented in the figures, high levels of toxic metals 
resulted in a decrease in the level of zinc and selenium. The same inverse correlation was found 
for the zinc to copper ratio and the levels of toxic metals.  
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 Table 3.   Concentration of toxic metals measured in patients with ADHD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 (a, b). Inverse relations between the levels of zinc and selenium in patients with ADHD 
and accumulated toxic metals in the body 
 
Effect of orthomolecular treatment (metabolic correction) on the level of metabolic stress 
and fatty acid composition in patients with ADHD 
Treatment was performed according to principles of integrative management of this condition, 
and patients were treated by essential fatty acids, amino acids, minerals, probiotics and vitamins. 
The list of the medicine (nutraceuticals) that were prescribed in different combination (mixed 
composition) depending on the laboratory testing of the deficiencies in patients is shown in Table 
4. 
Concentration of toxic metals measured in patients with ADHD (hair analysis) 
Toxic metal  Average 
(ppm)  SD  Maximum level (ppm) 
Aluminum  8.32  7.7  55 
Lead  1.3  1.5  9.4 
Mercury  0.42  0.34  1.8 
Arsenic  0.29  0.45  2.3 
Cadmium  0.11  0.16  1.4 
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Table 4.   List of prescribed nutraceuticals.  
Patients received only some of these supplements depending of their metabolic profile.  
  
Biotin 5000 Mcg #60 Caps  Glycine Sticks 30 Sticks 
Pantothenic  Acid  500mg- 
#100 
Bk  Currant  Seed  500mg  #90 
Softgels  Immuno Pro 10.6 Oz  Potassium Gluc 98mg #100 
Borax 100 Tabs  L Tryptophan 60 Caps 500mg  Pro DHA 1000 Mg 60 Tabs 
Cal/Mag/Zinc #240 Caps  L-Arginine 500 Mg #100  Prodophilus 
Calcium Gluconate IV 1cc  Latero Flora Caps #60  ProEFA-90 Caps 1000mg 
Captomer 65 Mg #45 Caps  Lecithin 21 Gr #100 Softgels  ProEPA  60 Count 1000mg 
Catemine (Tyrosine/B6) #120  L-Glutamine 500 Mg #90 Caps  ProOmega Liquid-4 Oz 
Co  Enzyme  Q-10  400  Mg  30 
Tabs  Lipoic Acid- 100 Mg- 90 Caps  Quercetin/Bromelain #180 
Cod Liver Oil 100 Caps  L-Lysine 500 Mg #50 
Selenium-  200mcg-  #180 
Caps 
DHAJunior-250 mg- 180 Caps  L-Ornithine- 500 MG- 100 Caps 
Solar  D  Gems  4000  IU  120 
Caps 
Digestive Enzymes #250 Tabs  L-Taurine #100- 500mg  Solution Of Magnesium 8 Oz 
DL-Methionine  500  Mg  #250 
Caps  L-Threonine 500mg- #100 
Vit  D3-50,  50,000  IU  100 
Caps 
DL-Phenylalanine 500 mg #100  L-Tryptophan 500mg #60 Caps 
Vitamin  A  10000  IU-  100 
Softgels 
DMG  #60 Tabs  Lutein- 20 Mg- 60 Caps  Vitamin B1 100mg #100 Caps 
EnteroPro 60 Caps 
Methylcobalamin  5000mcg  60 
Tabs  Vitamin B2 100mg- 100caps 
Evening Primrose Oil #100- 500 
Mg Softgel  MSM Powder 200 Gr 
Vitamin  B6  (Pyridoxine)  IV 
Infusion 1cc 
Flaxseed Oil Cap #90 1000 Mg 
Softgel  NAC 600 Mg 60 Caps  Vitamin C 1 Gram #250 
Folic Acid-800 mcg- 100 Caps.  Niacin 50 Mg 300 Tabs 
Vitamin D 2000 IU-120 Soft 
Gels 
Gaba Caps 750 Mg-60 Caps  Niacinamide 50 mg #250  Vitamin E 100 IU #250 
Gentle Iron  25mg 90 Caps  Zinc Sulfate IV 10cc  Zinc Boost 
Glucosamine Sulf 500 Mg- 180 
Caps       Functional Foods in Health and Disease 2013; 3(1):1-20     Page 15 of 20                                                 
As the result of treatment, there were changes in the balance of omega 6 and omega 3 fatty acids. 
Data in Figure 8 show the examples of the improvement in the ratio of omega 6/omega 3 after 
treatment. 
 
Figure 8.   Improvement in the ratio of omega 6 to omega 3 fatty acids after treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In addition, for patients who had levels of EPA in plasma at the lower level of the reference 
range (0.2%-0.3%), these values were increased 2-5 times after 120-500 days of treatment.  The 
level of metabolic stress evaluated by the pyrroles was improved in 80% of patients (Figure 9).   
 
Figure 9.   Percentage of patients demonstrated improvement or progression of the stress levels 
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Data of the percentage of improvement in the pyrroles’ values (decrease excessive), days of 
treatment, age and sex of patients are shown in Table 5.    
 
Table 5.  Percentage of improvement of the pyrroles’ values in patients with ADHD 
                                                   
Deficiencies  of  essential  metals  such  as  zinc  and  magnesium  were  also  improved  by  the 
supplementation.  Combined magnesium and zinc uptake for 3 to 24 weeks restored normal Mg 
and Zn values in hair and red blood cells.  
 
CONCLUSION:  
According to these data, the metabolic correction of ADHD by supplementation with minerals, 
vitamins,  omega-3/omega-6  essential  fatty  acids,  and  amino  acids  can  ameliorate  ADHD 
symptoms.  After the intervention, 80% of children treated  from  several weeks  to  1-2  years, 
demonstrated an improvement of metabolic stress level measured by level of pyrroles. For these 
patients the levels of EPA were increased and the ratio omega6/omega 3 was improved.   
Putting all data together, it was demonstrated that after consumption of a combination of 
fatty acids as well as magnesium and zinc, amino acids, vitamins and probiotics most subjects 
had  a  considerable  reduction  in  markers  of  metabolic  stress  and  reported  less  emotional 
problems.  
In this study, it was demonstrated that metabolic correction of biochemical disturbances 
using  essential  fatty  acids,  amino  acids,  and  minerals  can  improve  fatty  acid  profiles  and 
metabolic  stress  levels.  These  disturbances  or  variations  from  reference  values  have  been 
associated with behavior typical of ADHD.  
Further  studies  need  to  be  conducted  with  integrative  metabolic  correction  therapy  to 
determine its value in the management of ADHD. 
 
Age  Sex 
Initial 
value  of 
pyrrole 
(ug/dL) 
Percentage  of 
improvement  
Days  of 
treatment   Age  Sex 
Initial 
value  of 
pyrrole 
(ug/dL) 
Percentage  of 
improvement  
Days  of 
treatment  
9.0  F  48  33.33  167  13.3  M  28  50.00  127 
8.5  F  25  40.00  63  15.9  M  26  84.62  167 
14.7  F  41  53.66  95  10.2  M  481  92.72  25 
9.9  M  34  52.94  80  10.3  M  35  62.86  136 
6.0  M  36  27.78  141  18.9  F  28  42.86  63 
7.5  M  34  -70.59  37  11.7  M  123  50.41  26 
8.5  M  26  65.38  86  11.8  M  61  68.85  102 
7.5  M  112  87.50  91  3.4  F  28  67.86  687 
5.1  M  25  40.00  63  7.7  M  25  -12.00  193 
22.8  M  52  61.54  110  7.9  F  24  66.67  149 
10.6  M  21  -66.67  78  22.4  M  30  50.00  174 
2.7  M  31  38.71  379  12.8  M  27  55.5  191 Functional Foods in Health and Disease 2013; 3(1):1-20     Page 17 of 20                                                 
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